Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Oct
08
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease
Pediatric Bone Sarcoma Gets First NCCN Guidelines
2026 Albany Prize Awardees Announced
ACS Study Quantifies Financial Burden of Cancer in Older Patients
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo